JAZZ - Jazz Pharmaceuticals plc
154.09 0.00 (0.00%)
After hours: 4:09PM EDT
| Previous Close | 154.67 |
| Open | 155.48 |
| Bid | 153.59 x 200 |
| Ask | 154.26 x 300 |
| Day's Range | 153.55 - 156.05 |
| 52 Week Range | 128.58 - 163.75 |
| Volume | 185,563 |
| Avg. Volume | 412,908 |
| Market Cap | 9.215B |
| Beta | 1.31 |
| PE Ratio (TTM) | 19.36 |
| EPS (TTM) | 7.96 |
| Earnings Date | May 7, 2018 - May 11, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 182.54 |
- Yahoo Finance Contributors•4 days ago
5 Trade Ideas for Monday: Globus Medical, Interactive Brokers, Infinera, Jazz Pharmaceuticals & Kansas City Southern
- PR Newswire•2 days ago
Jazz Pharmaceuticals to Report 2018 First Quarter Financial Results on May 8, 2018
DUBLIN , April 24, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2018 first quarter financial results on Tuesday, May 8, 2018 , after the close of ...
- Market Realist•7 days ago
Jazz Pharmaceuticals’ 2018 Guidance and Analyst Recommendations
Jazz Pharmaceuticals (JAZZ) estimates that in fiscal 2018, its net revenue will be $1.86 billion–$1.93 billion. Its estimated GAAP (generally accepted accounting principles) gross margin is 93% for 2018.
Market Realist•7 days agoVyxeos Could Be Jazz Pharmaceuticals’ Long-Term Growth Driver
In 4Q17, Jazz Pharmaceuticals’ (JAZZ) Vyxeos (daunorubicin and cytarabine) generated revenues of $24 million compared to $10 million in 3Q17. In fiscal 2017, Vyxeos reported net revenues of $34 million.
- Market Realist•8 days ago
Jazz Pharmaceuticals’ Xyrem, Erwinase, and Defitelio
In 4Q17, Jazz Pharmaceuticals’ (JAZZ) Xyrem generated revenues of $312.5 million compared to $291 million in 4Q16. In fiscal 2017, Xyrem reported revenues of $1.2 billion compared to $1.1 billion in 2016, which reflected a 7% growth on a YoY basis. Xyrem is used for the treatment of cataplexy in narcolepsy and excessive daytime sleepiness in narcolepsy.
- Market Realist•8 days ago
Jazz Pharmaceuticals: How It’s Positioned before 1Q18
In 4Q17, Jazz Pharmaceuticals (JAZZ) generated revenues of $436.4 million compared to $396.6 in 4Q16, which reflected a 10% growth on a YoY (year-over-year) basis and a 6% growth quarter-over-quarter.
- GlobeNewswire•17 days ago
Research Report Identifies Yirendai, Atlantic Capital Bancshares, Jazz Pharmaceuticals, Sina, Akebia Therapeutics, and SMART Global with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, April 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Markit•27 days agoSee what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.
Jazz Pharmaceuticals PLC NASDAQ/NGS:JAZZ
- Benzinga•last month
Jazz Pharma Upgraded On Bullish Pipeline Forecast, Earnings Growth Visibility, M&A Potential
Morgan Stanley named three reasons for its positive opinion on Irish pharma company Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) in a Monday report. The Analyst Analyst David Risinger upgraded shares of Jazz ...
- Zacks•last month
Should Value Investors Pick Jazz Pharmaceuticals (JAZZ) Stock?
Is Jazz Pharmaceuticals (JAZZ) a great pick from the value investor's perspective right now? Read on to know more.
Markit•last monthSee what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.
Jazz Pharmaceuticals PLC NASDAQ/NGS:JAZZ
- GlobeNewswire•last month
New Research: Key Drivers of Growth for Jazz Pharmaceuticals, Armstrong World Industries, Banco Latinoamericano de Comercio Exterior, S.A, Mercury, Canadian National Railway, and Bank of Nova Scotia — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, March 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- Investopedia•2 months ago
Why Biotech Stocks Face Steep Declines Ahead
The biotech sector could sink in the near term amid signs of deteriorating technicals.
- PR Newswire•2 months ago
Jazz Pharmaceuticals Announces Participation in Two Investor Conferences in March
Cowen and Company 38th Annual Healthcare Conference in Boston, MA on Tuesday, March 13, 2018 at 8:00 a.m. EDT / 12:00 p.m. GMT. Bruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a business and financial update. Barclays Global Healthcare Conference in Miami, FL on Wednesday, March 14, 2018 at 8:00 a.m. EDT / 12:00 p.m. GMT. Matt Young, executive vice president and chief financial officer, will provide an overview of the company and a business and financial update. A live audio webcast of each presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.
- PR Newswire•2 months ago
Jazz Pharmaceuticals Announces FDA Acceptance of NDA for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
DUBLIN, March 2, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing with standard review the company's New Drug Application (NDA) seeking marketing approval for solriamfetol, an investigational medicine for the treatment of excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea (OSA). The Prescription Drug User Fee Act (PDUFA) goal date for an FDA decision is December 20, 2018.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of JAZZ earnings conference call or presentation 27-Feb-18 9:30pm GMT
Q4 2017 Jazz Pharmaceuticals PLC Earnings Call
- Zacks•2 months ago
Jazz Pharmaceuticals (JAZZ) Q4 Earnings Miss, Sales Up Y/Y
Jazz Pharmaceuticals (JAZZ) earnings and revenues miss estimates in Q4. However, the company posts a strong bottom and top-line guidance for 2018.
- Associated Press•2 months ago
Jazz misses Street 4Q forecasts
The Dublin-based company said it had profit of $3.79 per share. Earnings, adjusted for one-time gains and costs, were $2.95 per share. The results fell short of Wall Street expectations. The average estimate ...
- Investor's Business Daily•2 months ago
Jazz Pharma's Fourth-Quarter Sales, Profit Lag; Guidance Mixed
Jazz reported adjusted income of $2.95 per share on sales of $436.4 million for its fourth quarter.
- PR Newswire•2 months ago
Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2017 Financial Results
Total Revenues of $1.6 Billion in 2017 GAAP EPS of $7.96 Per Share in 2017 Adjusted Non-GAAP EPS of $11.04 Per Share in 2017 Solriamfetol New Drug Application Submitted in December 2017 DUBLIN , Feb. 27, ...
- ACCESSWIRE•2 months ago
Jazz Pharmaceuticals Plc to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 27, 2018 / Jazz Pharmaceuticals Plc (NASDAQ: JAZZ ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 27, 2018 at 4:30 PM Eastern ...
- Benzinga•2 months ago
Jazz Pharmaceuticals Q4 Earnings Outlook
On Tuesday, Jazz Pharmaceuticals (NASDAQ: JAZZ ) will release its latest earnings report. Here is Benzinga's outlook for the company. Earnings and Revenue Wall Street expects EPS of $3.00 and sales around ...
- ACCESSWIRE•2 months ago
Wired News - Jazz Pharma Enrolled First Patient in Phase-2 Clinical Trial Assessing Defibrotide for the Prevention of Acute Graft-versus-Host Disease
Stock Monitor: Anika Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 27, 2018 / Active-Investors.com has just released a free research report on Jazz Pharma PLC (NASDAQ: JAZZ ). ...
- Benzinga•2 months ago
The Week Ahead In Biotech: Earnings, PDUFA Dates And More
The number of biotech stocks posting gains outstripped those recording losses for the week. Notable among the gainers for the week were Odonate Therapeutics Inc (NASDAQ: ODT ) — which reported its financial ...
- PR Newswire•2 months ago
Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating Defibrotide for the Prevention of Acute Graft-versus-Host Disease
DUBLIN , Feb. 23, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled in a Phase 2 clinical trial evaluating the efficacy and safety ...
